In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...

The FDA has approved narsoplimab (Yartemlea) as the first treatment for hematopoietic stem cell transplant (HSCT)-associated ...

An evidence-based exploration of how culinary botanicals synergize with cannabinoids to create pharmacologically active, ...

Pain represents the cardinal symptom of osteoarthritis, yet its intensity, quality, and impact vary dramatically among ...

Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker ...

The firm is also calling for measures to support the green transition and the workforce Read more at The Business Times.

Cancer immunotherapy has been transformed by engineered T cells, but those bespoke treatments are slow, expensive, and out of ...

Could diabetes medications have an influence beyond simply regulating blood sugar? This question is gaining ground in ...

Many novel treatment approaches are being investigated to halt progression of geographic atrophy (GA) or, potentially, even reverse the retinal damage. The major categories include novel complement ...

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...